Novartis's dovitinib fails pivotal trial
This article was originally published in Scrip
Executive Summary
Novartis's dovitinib (TKI258), a tyrosine kinase inhibitor coming late to the already crowded field in renal cell carcinoma, has failed a pivotal Phase III trial. The news was tucked away in a 70-page quarterly financial update.